---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-029541"
form_type: "8-K"
ticker: "LSTA"
cik: "0000320017"
company_name: "LISATA THERAPEUTICS, INC."
filed_at: "2026-07-24T16:15:36+00:00"
generated_at: "2026-07-24T16:16:03.865090+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Lisata Therapeutics terminates merger with Kuva Labs; Kuva failed to secure financing

## Summary
- Merger agreement terminated after Kuva Labs failed to obtain financing to fund tender offer.
- Kuva must pay Lisata a $2M termination fee under the agreement.
- Lisata reserves rights to seek damages for willful breach; no assurance of recovery.
- Board to assess strategic alternatives including reverse merger, business combination, asset sales, or dissolution.
- No timetable set for strategic review; no assurance of any transaction.

## SEC filing metadata
- accession: 0001140361-26-029541
- form_type: 8-K
- ticker: LSTA
- cik: 0000320017
- company_name: LISATA THERAPEUTICS, INC.
- filed_at: 2026-07-24T16:15:36+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/320017/000114036126029541/0001140361-26-029541-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/320017/000114036126029541/ef20078724_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-029541
- JSON: https://secwatch.observer/filing/0001140361-26-029541.json
- Plain text: https://secwatch.observer/filing/0001140361-26-029541.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.